secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atrium Therapeutics, Inc. (RNA)
CIK:        0002093101
Form:       8-K/A
Filed at:   2026-10-09T10:17:57+00:00
Accession:  0001193125-26-418417
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 8.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Atrium Therapeutics corrects post-PIPE share count to 21,571,507, including make-whole spin-off shares
--------------------------------------------------------------------------------

- PIPE securities purchase agreement dated Oct. 7, 2026 with accredited investors covers 5,170,384 common shares plus pre-funded warrants for up to 1,134,930 shares.
- Amendment No. 1 restates shares outstanding after the offering as 21,571,507, correcting the number in the original Oct. 8, 2026 Form 8-K; no other information revised.
- That total includes shares issued to settle make-whole equity awards granted in connection with the Company's spin-off from Avidity Biosciences, Inc.
- Closing of the offering remains subject to conditions; the company flags risk that it or the PIPE Investors may fail to satisfy them.
- Amendment signed Oct. 9, 2026 by Chief Executive Officer Kathleen Gallagher.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2093101/000119312526418417/0001193125-26-418417-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2093101/000119312526418417/d173581d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-418417

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer